192 related articles for article (PubMed ID: 32574505)
1. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
[No Abstract] [Full Text] [Related]
2. A new therapy for systemic sclerosis-associated interstitial lung disease.
Kondoh Y
Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
4. David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
Miniati I; Conforti ML; Guiducci S; Matucci Cerinic M
Clin Exp Rheumatol; 2007; 25(2):169-71. PubMed ID: 17543137
[No Abstract] [Full Text] [Related]
5. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
Bredemeier M
Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
[No Abstract] [Full Text] [Related]
6. Nintedanib for systemic sclerosis-associated interstitial lung disease.
Rahimi S
Lancet Respir Med; 2020 Feb; 8(2):136. PubMed ID: 31932219
[No Abstract] [Full Text] [Related]
7. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
8. Senescence Signature in Skin Biopsies From Systemic Sclerosis Patients Treated With Senolytic Therapy: Potential Predictor of Clinical Response?
Martyanov V; Whitfield ML; Varga J
Arthritis Rheumatol; 2019 Oct; 71(10):1766-1767. PubMed ID: 31112009
[No Abstract] [Full Text] [Related]
9. Multiple eruptive dermatofibromas aggravated by mycophenolate mofetil and pirfenidone in a patient with systemic sclerosis.
Wang R; Li G; Nong L; Wang M
Rheumatology (Oxford); 2020 Dec; 59(12):4000-4001. PubMed ID: 32572469
[No Abstract] [Full Text] [Related]
10. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al.
Bredemeier M
Arthritis Rheumatol; 2021 Dec; 73(12):2353-2354. PubMed ID: 34105307
[No Abstract] [Full Text] [Related]
12. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease.
Gkiouras K; Grammatikopoulou MG; Simopoulou T; Daniil Z; Bogdanos DP
Clin Rheumatol; 2021 Aug; 40(8):3379-3380. PubMed ID: 34213671
[No Abstract] [Full Text] [Related]
14. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
15. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
16. Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.
Seibold JR; Kohlbrenner V; Alves M; Distler O
Ann Rheum Dis; 2022 Dec; 81(12):e251. PubMed ID: 33023957
[No Abstract] [Full Text] [Related]
17. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
[No Abstract] [Full Text] [Related]
19. Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.
Duarte AC; Vinagre F; Soares J; Cordeiro A
Acta Reumatol Port; 2019; 44(2):161-162. PubMed ID: 31280278
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.
Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S
J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
